Nationwide prospective and retrospective surveys for hepatitis B virus reactivation during immunosuppressive therapies

Journal of Gastroenterology

Volumn 51, Issue 10, 2016, Pages 999-1010

  Mochida, Satoshi ^a   Nakao, Masamitsu ^a   Nakayama, Nobuaki ^a   Uchida, Yoshihito ^a   Nagoshi, Sumiko ^a   Ido, Akio ^b   Mimura, Toshihide ^a   Harigai, Masayoshi ^c   Kaneko, Hiroshi ^d   Kobayashi, Hiroko ^e   Tsuchida, Tetsuya ^a   Suzuki, Hiromichi ^a   Ura, Nobuyuki ^f   Nakamura, Yuichi ^a   Bessho, Masami ^a   Dan, Kazuo ^g   Kusumoto, Shigeru ^h   Sasaki, Yasutsuna ^a   Fujii, Hirofumi ⁱ   Suzuki, Fumitaka ^j   Ikeda, Kenji ^j   Yamamoto, Kazuhiko ^k   Takikawa, Hajime ^l   Tsubouchi, Hirohito ^b   Mizokami, Masashi ^d   more..

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

^b KAGOSHIMA UNIVERSITY   (Japan)

^c TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^d NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^e FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^f TEINE KEIJINKAI HOSPITAL   (Japan)

^g NIPPON MEDICAL SCHOOL   (Japan)

^h NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

ⁱ JICHI MEDICAL UNIVERSITY   (Japan)

^j TORANOMON HOSPITAL   (Japan)

^k UNIVERSITY OF TOKYO   (Japan)

^l TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

more..

Author keywords

Acute liver failure; De novo hepatitis B; HBV reactivation; Immunosuppressive therapy

Indexed keywords

ADALIMUMAB; ALKYLATING AGENT; AZATHIOPRINE; CALCINEURIN INHIBITOR; CYCLOPHOSPHAMIDE; DAUNORUBICIN; DOCETAXEL; ENTECAVIR; EPIRUBICIN; EVEROLIMUS; FLUOROURACIL; FOLINIC ACID; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; IRINOTECAN; METHOTREXATE; MYCOPHENOLATE MOFETIL; OXALIPLATIN; PANITUMUMAB; PREDNISOLONE; RITUXIMAB; SORAFENIB; TACROLIMUS; TEMOZOLOMIDE; UNINDEXED DRUG; VINCRISTINE; VIRUS DNA; ANTINEOPLASTIC AGENT;

ACUTE LIVER FAILURE; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CHILD; CLINICAL FEATURE; FEMALE; HEPATITIS B; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER FAILURE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; SIDE EFFECT; VERY ELDERLY; VIRUS REACTIVATION; ADVERSE EFFECTS; BLOOD; CHRONIC HEPATITIS B; COMPLICATION; HEPATITIS B VIRUS; IMMUNOLOGY; INFANT; JAPAN; MIDDLE AGED; PHYSIOLOGY; PRESCHOOL CHILD; VIROLOGY; VIRUS ACTIVATION; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; DNA, VIRAL; FEMALE; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; INFANT; JAPAN; LIVER FAILURE, ACUTE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; VIRUS ACTIVATION; YOUNG ADULT;

EID: 84988864309     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-016-1168-2     Document Type: Article

References (27)

1. World Health Organization. Hepatitis: fact sheet N°204, July 2015. www.who.int/mediacentre/factsheets/fs204/en/.
2. Perz JF, Armstrong GL, Farrington LA, et al. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer world wide. J Hepatol. 2006;45:529–38.
3. Tanaka J, Kumagai J, Katayama K, et al. Sex- and age-specific carriers of hepatitis B and C virus in Japan estimated by the prevalence in the 3,485,648 first-time blood donors during 1995–2000. Intervirol. 2004;47:32–40.
4. Kusumoto S, Tanaka Y, Mizokami M, et al. Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma. Int J Hematol. 2009;90:13–23.
5. Wands JR, Chura CM, Roll FJ, et al. Serial studies of hepatitis-associated antigen and antibody in patients receiving antitumor chemotherapy for myeloproliferative and lymphoproliferative disorders. Gastroenterology. 1975;68:105–12.
6. Lok AS, Liang RH, Chiu EK, et al. Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology. 1991;100:182–8.
7. Uemoto S, Sugiyama K, Marusawa H, et al. Transmission of hepatitis B virus from hepatitis B core antibody-positive donors in living related liver transplants. Transplantation. 1998;65:494–9.
8. Dervite I, Hober D, Morel P. Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med. 2001;344:68–9.
9. Barone M, Notarnicola A, Lopalco G, et al. Safety of long-term biologic therapy in rheumatologic patients with a previously resolved hepatitis B viral infection. Hepatology. 2015;62:40–6.
10. Urata Y, Uesato R, Tanaka D, et al. Prevalence of reactivation of hepatitis B virus replication in rheumatoid arthritis patients. Mod Rheumatol. 2011;21:16–23.
11. Mori S. Past hepatitis B infection in rheumatoid arthritis patients receiving biologic and/or nonbiologic disease-modifying antirheumatic drugs. Mod Rheumatol. 2011;21:621–7.
12. Tamori A, Koike T, Goto H, et al. Prospective study of reactivation of hepatitis B in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts. J Gastroenterol. 2011;46:556–64.
13. Oketani M, Ido A, Uto H, et al. Prevention of hepatitis B virus reactivation in patients receiving immunosuppressive therapy or chemotherapy. Hepatol Res. 2012;42:627–36.
14. Drafting Committee for Hepatitis Management Guidelines and the Japan Society of Hepatology. JSH guidelines for the management of hepatitis B virus infection. Hepatol Res. 2014;44(Suppl S1):1–58.
15. Mochida S, Takikawa Y, Nakayama N, et al. Diagnostic criteria of acute liver failure: a report by the intractable hepato-biliary diseases study group of Japan. Hepatol Res. 2011;41:805–12.
16. Sugawara K, Nakayama N, Mochida S. Acute liver failure in Japan: definition, classification, and prediction of the outcome. J Gastroenterol. 2012;47:849–61.
17. Mochida S, Takikawa Y, Nakayama N, et al. Classification of the etiologies of acute liver failure in Japan: a report by the intractable hepato-biliary diseases study group of Japan. Hepatol Res. 2014;44:365–7.
18. Allice T, Cerutti F, Pittaluga F, et al. COBAS AmpliPrep-COBAS TaqMan hepatitis B virus (HBV) test: a novel automated real-time PCR assay for quantification of HBV DNA in plasma. J Clin Microbiol. 2007;45:828–34.
19. Fujiwara K, Mochida S, Matsui A, et al. Intractable liver diseases study group of Japan. Fulminant hepatitis and late onset hepatic failure in Japan: summary of 698 patients between 1998 and 2003 analyzed by the annual nationwide survey. Hepatol Res. 2008;38:646–57.
20. Oketani M, Ide A, Nakayama N, et al. Etiology and prognosis of fulminant hepatitis and late-onset hepatic failure in Japan: summary of the annual nationwide survey between 2004 and 2009. Hepatol Res. 2013;43:97–105.
21. Reddy KR, Beavers KL, Hammond SP, et al. American gastroenterological association institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology. 2015;148:215–9.
22. Dickson RC, Terrault NA, Ishitani M, et al. Protective antibody levels and dose requirements for IV 5 % Nabi hepatitis B immune globulin combined with lamivudine in liver transplantation for hepatitis B-induced end stage liver disease. Liver Transpl. 2006;12:124–33.
23. Knöll A, Boehm S, Hahn J, et al. Long-term surveillance of haematopoietic stem cell recipients with resolved hepatitis B: high risk of viral reactivation even in a recipient with a vaccinated donor. J Viral Hepat. 2007;14:478–83.
24. Nakamoto S, Kanda T, Nakaseko C, et al. Reactivation of hepatitis B virus in hematopoietic stem cell transplant recipients in Japan: efficacy of nucleos(t)ide analogues for prevention and treatment. Int J Mol Sci. 2014;15:21455–67.
25. Kusumoto S, Tanaka Y, Suzuki R, et al. Monitoring of hepatitis B virus (HBV) DNA and risk of HBV reactivation in B-Cell lymphoma: a prospective observational study. Clin Infect Dis. 2015;61:719–29.
26. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009;50:661–2.
27. European Association for the Study of Liver. EASL clinical practical guidelines: management of alcoholic liver disease. J Hepatol. 2012;57:399–420.